Radio-iodine therapy in differentiated thyroid cancer: indications and procedures

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 6, 2008, Pages 989-1007

  Reiners, Christoph ^a   Dietlein, Markus ^b   Luster, Markus ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

differentiated thyroid cancer; dosimetry; guidelines; radio iodine therapy; recombinant human thyrotropin; side effects

Indexed keywords

AZACITIDINE; BEXAROTENE; CORTICOSTEROID; DEPSIPEPTIDE; GLUCOCORTICOID; IODINE; IODINE 123; IODINE 124; IODINE 131; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; RETINOIC ACID; ROSIGLITAZONE; THYROTROPIN; TRICHOSTATIN A; VALPROIC ACID;

ADJUVANT THERAPY; AMENORRHEA; AZOOSPERMIA; BONE MARROW DEPRESSION; BONE METASTASIS; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; DENTAL CARIES; DIET RESTRICTION; DOSIMETRY; FAMILY HISTORY; FAMILY PLANNING; GASTRITIS; HISTOPATHOLOGY; HUMAN; HYPOTHYROIDISM; INDIVIDUALIZATION; LEUKOPENIA; LUNG FIBROSIS; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; METASTASIS POTENTIAL; MORBIDITY; OLIGOMENORRHEA; OLIGOSPERMIA; PATIENT DECISION MAKING; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RADIATION DOSE; REVIEW; SIALOADENITIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SJOEGREN SYNDROME; SPINE METASTASIS; THROMBOCYTOPENIA; THYROID CANCER; THYROID PAPILLARY CARCINOMA; THYROID SURGERY; TREATMENT INDICATION; TUMOR LOCALIZATION; TUMOR VOLUME; WHOLE BODY SCINTISCANNING; XEROSTOMIA;

CARCINOMA, PAPILLARY, FOLLICULAR; HUMANS; IODINE RADIOISOTOPES; THYROID HORMONES; THYROID NEOPLASMS;

EID: 56849086574     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.09.013     Document Type: Review

References (69)

1. Cooper D.S., Doherty G.M., Haugen B.R., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 (2006) 1-33
2. AACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocrine Practice 12 (2006) 63-102
3. Pacini F., Schlumberger M., Harmer C., et al. Post-surgical use of radioiodine (I-131) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. European Journal of Endocrinology 153 (2005) 651-659
4. Pacini F., Schlumberger M., Dralle H., et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 154 (2006) 787-803
5. Luster M., Clarke S.E., Dietlein M., et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 35 (2008) 1941-1959
6. Sawka A.M., Thephamongkhol K., Brouwers M., et al. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 3668-3676
7. Pelizzo M.R., Boschin I.M., Toniato A., et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a monoinstitutional 12-year experience. Nuclear Medicine Communications 25 (2004) 547-552
8. Machens A., Holzhausen H.J., and Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 103 (2005) 2269-2273
9. Dietlein M., Dressler J., Escher W., et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). Nuklearmedizin 46 (2007) 213-219 [German]
10. Rahbar K, Hutzenlaub V, Fischer RJ, et al. Comparative study on the radioiodine ablation in small papillary and follicular thyroid carcinomas (≤1 cm). Nuklearmedizin, in press.
11. Lassmann M., Luster M., Hänscheid H., et al. Impact of (131)I diagnostic activities on the biokinetics of thyroid remnants. Journal of Nuclear Medicine 45 (2004) 619-625
12. Freudenberg L, Jentzen W, Görges R, et al. 124I-positron emission tomography dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 46, in press.
13. Serhal D.I., Nasrallah M.P., and Arafah B.M. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 3285-3289
14. Pacini F., Ladenson P.W., Schlumberger M., et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 926-932
15. Haenscheid H., Lassmann M., Luster M., et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Journal of Nuclear Medicine 47 (2006) 648-654
16. Luster M., Sherman S.I., Skarulis M.C., et al. Comparison of radioiodine biokinetics following the administration of Recombinant Human Thyroid Stimulating Hormone (rhTSH) and after thyroid hormone withdrawal in thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 30 (2003) 1371-1377
17. Löffler M., Weckesser M., Franzius C., et al. Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma. Nuklearmedizin 42 (2003) 240-243
18. Mernagh P., Campell S., Dietlein M., et al. Cost-effectiveness of using recombinant human TSH (rhTSH) prior to radioiodine therapy ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. European Journal of Endocrinology 155 (2006) 405-414
19. Duntas L.H., and Biondi B. Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. European Journal of Endocrinology 156 (2007) 13-19
20. Tuttle R.M., Brokhin M., Omry G., et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. Journal of Nuclear Medicine 49 (2008) 764-770
21. Barbaro D., Boni G., Meucci G., et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. The Journal of Clinical Endocrinology 88 (2003) 4110-4115
22. Pilli T., Brianzoni E., Capoccetti F., et al. A comparison of 1850 (50 mCi) and 3700 (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. The Journal of Clinical Endocrinology and Metabolism 92 (2007) 3542-3546
23. Barbaro D., Boni G., Meucci G., et al. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nuclear Medicine Communications 27 (2006) 627-632
24. Pacini, Molinari E., Castagna M.G., et al. Ablation of thyroid remnants with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 4063-4068
25. Lassmann M., and Hänscheid H. Spatial dose mapping for individualizing radioiodine treatment. Journal of Nuclear Medicine 48 (2007) 2-4
26. Lassmann M., Hänscheid H., Chiesa C., et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. European Journal of Nuclear Medicine and Molecular Imaging 35 (2008) 1405-1412
27. Benua R.S., Cicale N.R., Sonenberg M., et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR. American Journal of Roentgenology 87 (1962) 171
28. Maxon H.R., Thomas S.R., Boehringer A., et al. Low iodine diet in 131I ablation of thyroid remnants. Clinical Nuclear Medicine 8 (1983) 123-126
29. Schlumberger M., De Vathaire F., Ceccarelli C., et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. Journal of Nuclear Medicine 37 (1996) 606-612
30. Krassas G.E., and Pontikides N. Gonadal effect of radiation from 131I in male patients with thyroid carcinoma. Archives of Andrology 51 (2005) 171-175
31. Ceccarelli C., Battisti P., Gasperi M., et al. Radiation dose to the testes after 131I therapy for ablation of postsurgical remnants in patients with differentiated thyroid cancer. Journal of Nuclear Medicine 40 (1999) 1716-1721
32. Dottorini M.E., Lomuscio G., Mazzucchelli L., et al. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. Journal of Nuclear Medicine 36 (1995) 21-27
33. Yamamoto Y., Nishiyama Y., Monden T., et al. Clinical usefulness of fusion of 131I SPECT and CT images in pateints with differentiated thyroid carcinoma. Journal of Nuclear Medicine 44 (2003) 1905-1910
34. Tharp K., Israel O., Hausmann J., et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 31 (2004) 1435-1442
35. Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 2892-2899
36. van Nostrand D., Atkins F., Yeganeh F., et al. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 12 (2002) 121-134
37. Dorn R., Kopp J., Vogt H., et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. Journal of Nuclear Medicine 44 (2003) 451-460
38. Tuttle R.M., Leboeuf R., Robbins R.J., et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. Journal of Nuclear Medicine 47 (2006) 1587-1591 Erratum in: J Nucl Med. 2007; 48: 7
39. Ilgan S., Karacalioglu A.O., Pabuscu Y., et al. Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 3 (2004) 825-830
40. Ronga G., Filesi M., Montesano T., et al. Lung metastases from differentiated thyroid carcinoma. A 40 years' experience. The Quarterly Journal of Nuclear Medicine and Molecular Imaging 48 (2004) 12-19
41. Schlumberger M., Challeton C., De Vathaire F., et al. Radioactive iodine treatment for lung and bone metastases from thyroid carcinoma. Journal of Nuclear Medicine 37 (1996) 598-605
42. Reiners C. Radioiodine therapy in patients with pulmonary metastases of thyroid cancer: when to treat, when not to treat?. European Journal of Nuclear Medicine and Molecular Imaging 30 (2003) 939-942
43. Bernier M.O., Leenhardt L., Hoang C., et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 1568-1573
44. Zettinig G., Fueger B.J., Passler C., et al. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma - surgery or conventional therapy?. Clinical Endocrinology 56 (2002) 377-382
45. Chiu A.C., Delpassand E.S., and Sherman S.I. Prognosis and treatment of brain metastases in thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism 82 (1997) 3637-3642
46. McWilliams R.R., Giannini C., Hay I.D., et al. Management of brain metastases from thyroid carcinoma: a study of 16 histopathologically confirmed cases over 25 years. Cancer 98 (2003) 356-362
47. Luster M., Lippi F., Jarzab B., et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer 12 (2005) 49-64
48. de Keizer B., Brans B., Hoekstra A., et al. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. European Journal of Nuclear Medicine and Molecular Imaging 30 (2003) 367-373
49. Pötzi C., Moameni A., Karanikas G., et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clinical Endocrinology 65 (2006) 519-523
50. Braga M., Ringel M.D., and Cooper D.S. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 5148-5151
51. Liu Y.Y., van der Pluijm G., Karperien M., et al. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies. Clinical Endocrinology 64 (2006) 617-624
52. Koong S.S., Reynolds J.C., Movius E.G., et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism 84 (1999) 912-916
53. Börner A.R., Petrich T., Weckesser E., et al. Monitoring isotretinoin therapy in the thyroid cancer using 18F-FDG-PET. European Journal of Nuclear Medicine and Molecular Imaging 29 (2002) 231-236
54. Grüning T., Tiepolt C., Zöphel K., et al. Retinoid acid for redifferentiation of thyroid cancer - does it hold its promise?. European Journal of Endocrinology 148 (2003) 395-402
55. Simon D., Korber C., Krausch M., et al. Clincal impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. European Journal of Nuclear Medicine and Molecular Imaging 29 (2002) 775-782
56. Oyen W.J.G., Bodei L., Giammarile F., et al. Targeted therapy in nuclear medicine - current status and future prospects. Annals of Oncology 18 (2007) 1782-1792
57. Haugen B.R. Redifferentiation therapy in advanced thyroid cancer. Current Drug Targets. Immune, Endocrine and Metabolic Disorders 4 (2004) 175-180
58. Schmutzler C. Regulation of the sodium/iodine symporter by retinoids - a review. Experimental and Clinical Endocrinology & Diabetes 109 (2001) 41-44
59. Liu Y.Y., Stokkel M.P., Morreau H.A., et al. Radioiodine therapy after pre-treatment with bexarotene for metastases of differentiated thyroid carcinoma. Clinical Endocrinology 68 (2008) 605-609
60. Schlumberger M., Mancusi F., Baudin E., et al. 131-I therapy for elevated thyroglobulin levels. Thyroid 7 (1997) 273-276
61. Pineda J.D., Lee T., Ain K., et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. The Journal of Clinical Endocrinology and Metabolism 80 (1995) 1488-1492
62. Pacini F., Agate L., Elisei R., et al. Outcome of differentiated thyroid cancer with detectable serum thyroglobulin and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 4092-4097
63. van Tol K.M., Jager P.L., de Vries E.G., et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. European Journal of Endocrinology 148 (2003) 589-596
64. Kabasakal L., Selcuk N.A., Shafipour H., et al. Treatment of iodine-negative thyreoglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. European Journal of Nuclear Medicine and Molecular Imaging 31 (2004) 1500-1504
65. Leboulleux S., Schroeder P.R., Schlumberger M., et al. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nature Clinical Practice. Endocrinology & Metabolism 3 (2007) 112-121
66. Zoller M., Kohlfuerst S., Igerc I., et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?. European Journal of Nuclear Medicine and Molecular Imaging 34 (2007) 487-495
67. Rubino C., de Vathaire F., Dottorini M.E., et al. Second primary malignancy in thyroid cancer patients. British Journal of Cancer 89 (2003) 1638-1644
68. Bhattacharyya N., and Chien W. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. The Annals of Otology, Rhinology, and Laryngology 115 (2006) 607-610
69. Alexander C., Bader J.B., Schäfer A., et al. Intermediate and long-termn side effects of high-dose radioiodine therapy for thyroid carcinoma. Journal of Nuclear Medicine 39 (1998) 1551-1554